Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins

Lipoprotein Metabolism in Normal Volunteers and Hyperlipoproteinemic Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00001154

Enrollment

759

Registered

1999-11-04

Start date

1976-09-03

Completion date

Unknown

Last updated

2026-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia, Hypercholesterolemia, Hyperlipidemia, Hypolipoproteinemia

Keywords

Metabolism, HDL, Cholesterol, LDL, Hypoalphalipoproteinemia, Natural History

Brief summary

Researchers plan to study the fat-rich particles, called lipoproteins, which circulate in the blood. This study is designed to improve understanding of normal, as well as abnormal, lipoprotein metabolism and the role it plays in the development of hardening of the arteries (atherosclerosis). Patients participating in this study will receive injections of lipoproteins or apolipoproteins (the protein component of lipoproteins) that have been isolated and purified. These lipoproteins will be labeled with small amounts of radioactive material and sterilized before they are injected into the patient. Patients participating in the study will be required to have blood samples taken, and provide urine samples throughout the course of the study. In addition, patient will be required to follow a specially formulated diet. Patients will be weighed throughout the course of the study.

Detailed description

We propose to investigate human in vivo lipoprotein metabolism using radiolabeled apolipoproteins on plasma lipoproteins. Paired kinetic studies using dual-labeled iodinated lipoproteins and apolipoproteins are performed in healthy volunteer controls with normal lipids and subjects with dyslipidemia under controlled metabolic conditions. Studies are designed to formulate metabolic pathways in patients with undefined genetic disorders of lipid metabolism as well as in healthy volunteers to provide original insights into normal and pathologic metabolic pathways. All kinetic data is computer analyzed to provide quantitative data and facilitate direct comparison of multiple studies.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* INCLUSION CRITERIA: Subjects with new and undefined dyslipidemia-particularly familial disorders with extreme phenotypes. Healthy normal volunteers - (18 years old or older) controls to investigate the formation of HDL for prebeta HDL. Euthyroid.

Exclusion criteria

Healthy control volunteers are initially screened for secondary causes of hyperlipidemia and are excluded if they have any clinically significant laboratory abnormality (i.e., liver disease, disease, kidney disease, endocrine disease,), chronic medical problems (i.e., hypertension, migraines, inflammatory bowel, hepatitis, HIV) or require any chronic medications (i.e., acne, asthma). The healthy control volunteers weight must fall within the current guidelines for ideal body weight. Pregnant women. Unwilling to follow metabolic diet. Allergic to iodine. Unable to sign consent form.

Design outcomes

Primary

Measure	Time frame	Description
No outcome. This is a disease discover protocol.	5 years	Dyslipidemia

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORRobert D Shamburek, M.D.

National Heart, Lung, and Blood Institute (NHLBI)

Outcome results